Pharmacokinetic interactions related to the chemical structures of fluoroquinolones

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue SUPPL. A, 1996, Pages 41-55

  Mizuki, Yasuyuki ^a   Fujiwara, Iwao ^a   Yamaguchi, Toshikazu ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CAFFEINE; CIPROFLOXACIN; CYTOCHROME P450; ENOXACIN; FLEROXACIN; LOMEFLOXACIN; METHYLXANTHINE; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; THEOPHYLLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG STRUCTURE; NONHUMAN; RAT;

EID: 0029891142     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.suppl_a.41     Document Type: Article

References (46)

1. Andriole, V. T. (1993). The future of the quinolones. Drugs 45, Suppl. 3, 1-7.
2. Baenziger, N. C., Fox, C. L. & Modak, S. L. (1986). The structure of silver pefloxacin, an antibiotic related to nalidixic acid. Acta Crystallography C42, 1505-9.
3. Berthou, F., Flinois, J., Ratanasavanh, D., Beaune, P., Riche, C. & Guillouzo, A. (1991). Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metabolism and Disposition 19, 561-7.
4. PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proceedings of the National Academy of Sciences of the United States of America 86, 7696-700.
5. Cole, A., Goodfield, J., Williams, D. R. & Midgley, J. M. (1984). The complexation of transition series metal ions by nalidixic acid. Inorganica Chimica Acta 92, 91-7.
6. Davey, P. G. (1988). Overview of drug interactions with the quinolones. Journal of Antimicrobial Chemotherapy 22, Suppl. C, 97-107.
7. Dawson, J. H., Andersson, L. A. & Sono, M. (1982). Spectroscopic investigations of ferric cytochrome P-450-CAM ligand complexes. Journal of Biological Chemistry 257, 3606-17.
8. Flor, S., Guay, D. R. P., Opsahl, J. A., Tack, K. & Matzke, G. R. (1990). Effects of magnesium-aluminum hydroxide and calcium carbonate antacid on bioavailability of ofloxacin. Antimicrobial Agents and Chemotherapy 34, 2436-8.
9. Frost, R. W., Lasseter, K. C., Noe, A. J., Shamblen, E. C. & Lettieri, J. T. (1992). Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrobial Agents and Chemotherapy 36, 830-2.
10. Frost, R. W., Lettieri, J. T., Noe, A., Shamblen, E. C. & Lasseter, K. (1989). Effect of aluminum hydroxide and calcium carbonate antacids on ciprofloxacin bioavailability. Clinical Pharmacology and Therapeutics 45, 165.
11. Fuhr, U., Anders, E. M., Mahr, G., Sörgel, F. & Staib, A. H. (1992a). Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrobial Agents and Chemotherapv 36, 942-48.
12. Fuhr, U., Doehmer, J., Battula, N., Wolfel, C., Kudla, C, Keita, Y. et al. (1992b). Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochemical Pharmacology 43, 225-35.
13. Fuhr, U., Wolff, T., Harder, S., Schymanski, P. & Staib, A. H. (1990). Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metabolism and Disposition 18, 1005-10.
14. Grygiel, J. J. & Birkett, D. J. (1980). Effect of age on pattern of theophylline metabolism. Clinical Pharmacology and Therapeutics 28, 456-62.
15. Janknegt, R. (1990). Drug interactions with quinolones. Journal of Antimicrobial Chemotherapy 26, Suppl. D, 7-29.
16. Kanemitsu, K., Hori, S., Yanagawa, A. & Shimada, J. (1994). Effect of ferrous sulfate on the pharmacokinetics of sparfloxacin. Chemotherapy (Tokyo) 42, 6-13.
17. Lode, H., Stuhlert, P., Depperman, K., Mainz, S. & Borner, K. (1989). Pharmacokinetics interactions between oral ciprofloxacin, ofloxacin and ferro-salts. In Program and Abstracts of the Twenty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, TX, 1989. Abstract 213. American Society for Microbiology, Washington, DC.
18. Lomaestro, B. M. & Bailie, G. R. (1995). Absorption interactions with fluoroquinolones: 1995 update. Drug Safety 12, 314-33.
19. Maesen, F. P., Teengs, J. P., Baur, C. & Davies, B. I. (1984). Quinolones and raised plasma concentrations of theophylline. Lancet ii, 530.
20. Miyamoto, T., Matsumoto, J., Chiba, K., Egawa, H., Shibamori, K., Minamida, A. et al. (1990). Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. Journal of Medicinal Chemistry 33, 1646-56.
21. Mizuki, Y., Fujiwara, I., Yamaguchi, T. & Sekine, Y. (1996). Structure-related inhibitory effect of antimicrobial enoxacin and derivatives on theophylline metabolism by rat liver microsomes. Antimicrobial Agents and Chemotherapy, in press.
22. Mizuki, Y., Kamaura, M., Yamaguchi, T., Sekine, Y. & Hashimoto, M. (1989a). Interaction of enoxacin with theophylline in rats. Arzneimittel-Forschung/Drug Research 39, 593-7.
23. Mizuki, Y., Yamaguchi, T., Sekine, Y. & Hashimoto, M. (1989b). Interaction of enoxacin with theophylline in rats. Chemotherapy (Tokyo) 37, 1071-9.
24. Mizuki, Y., Yamaguchi, T., Sekine, Y. & Hashimoto, M. (1991). Effect of sparfloxacin on pharmacokinetics of theophylline in rats. Xenobiotic Metabolism and Disposition (Tokyo) 6, 67-72.
25. Mulder, G. J., Nagelkerke, J. F., Tijdens, R. B., Wijnands, W. J. A. & Van der Mark, E. J. (1988). Inhibition of the oxidative metabolism of theophylline in isolated rat hepatocytes by the quinolone antibiotic enoxacin and its metabolite oxoenoxacin, but not by ofloxacin. Biochemical Pharmacology 37, 2565-8.
26. Nakamura, S., Minami, A., Nakata, K., Kurobe, N., Kouno, K., Sakaguchi, Y. et al. (1989). In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrobial Agents and Chemotherapy 33, 1167-73.
27. Nakano, M., Yamamoto, M. & Arita, T. (1973). Interactions of aluminum, magnesium, and calcium ions with nalidixic acid. Chemical and Pharmaceutical Bulletin 26, 1505-10.
28. Niki, Y., Soejima, R., Kawane, H., Sumi, M. & Umeki, S. (1987). New synthetic quinolone antibacterial agents and serum concentration of theophylline. Chest 92, 663-9.
29. Niki, Y., Sumi, M., Tsukiyama, K., Moriya, O., Umeki, S. & Soejima, R. (1988a). Effect of T-3262 on serum concentration of theophylline. Chemotherapy (Tokyo) 36, Suppl. 9, 201-7.
30. Niki, Y., Tasaka, Y., Kishimoto, T., Nakajima, M., Tsukiyama, K., Nakagawa, Y. et al. (1990). Effect of fleroxacin on serum concentration of theophylline. Chemotherapy (Tokyo) 38, Suppl. 2, 364-71.
31. Niki, Y., Tasaka, Y., Tsukiyama, K., Umeki, S., Watanabe, M. & Soejima, R. (1988b). Effect of NY-198 on serum concentration of theophylline. Chemotherapy (Tokyo) 36, Suppl. 2, 251-5.
32. Okazaki, O., Kurata, T. & Tachizawa, H. (1988). Studies on the mechanism of pharmacokinetic interaction of aluminum hydroxide, an antacid, with new quinolones in rats. Xenobiotic Metabolism and Disposition (Tokyo) 3, 1219-24.
33. Okimoto, N., Niki, Y., Sumi, M., Nakagawa, Y. & Soejima, R. (1991). Effect of sparfloxacin on serum concentration of theophylline. Chemotherapy (Tokyo) 39, Suppl. 4, 158-60.
34. Polk, R. (1989). Drug-drug interactions with ciprofloxacin and other fluoroquinolones. American Journal of Medicine 87, Suppl. 5A, 76-81.
35. Poulos, T. L., Finzel, B. C., Gunsalus, I. C., Wagner, G. C. & Kraut, J. (1985). The 2.6-Å crystal structure of Pseudomonas putida cytochrome P-450. Journal of Biological Chemistry 260, 16122-30.
36. Rogge, M. C., Solomon, W. R., Sedman, A. J., Welling, P. G., Toothaker, R. D. & Wagner, J. G. (1988). The theophylline-enoxacin interaction: I. Effect of enoxacin dose size on theophylline disposition. Clinical Pharmacology and Therapeutics 44, 579-87.
37. Sarkar, M., Polk, R. E., Guzelian, P. S., Hunt, C. & Karnes, H. T. (1990). In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrobial Agents and Chemotherapy 34, 594-9.
38. Shimada, J., Nogita, T. & Ishibashi, Y. (1993). Clinical pharmacokinetics of sparfloxacin. Clinical Pharmacokinetics 25, 358-69.
39. Shimada, J., Saito, A., Shiba, K., Hojo, T., Kaji, M., Hori, S. et al. (1991). Pharmacokinetics and clinical studies on sparfloxacin. Chemotherapy (Tokyo) 39, Suppl. 4, 234-44.
40. Shimada, J., Shiba, K., Oguma, T., Miwa, H., Yoshimura, Y., Nishikawa, T. et al. (1992). Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrobial Agents and Chemotherapy 36, 1219-24.
41. Sutor, D. J. (1958). The structures of the pyrimidines and purines. VI. The crystal structure of theophylline. Acta Crystallography 11, 83-7.
42. Wijnands, W. J. A., Van Herwaarden, C. L. A. & Vree, T. B. (1984). Enoxacin raises plasma theophylline concentrations. Lancet ii, 108-9.
43. Wijnands, W. J. A. & Vree, T. B. (1988). Interaction between the fluoroquinolones and the bronchodilator theophylline. Journal of Antimicrobial Chemotherapy 22, Suppl. C, 109-14.
44. Wijnands, W. J. A., Vree, T. B. & Van Herwaarden, C. L. A. (1985). Enoxacin decreases the clearance of theophylline in man. British Journal of Clinical Pharmacology 20, 583-8.
45. Wijnands, W. J. A., Vree, T. B. & van Herwaarden, C. L. A. (1986). The influence of quinolone derivatives on theophylline clearance. British Journal of Clinical Pharmacology 22, 677-83.
46. Yamaki, K., Miyatake, H., Taki, F., Suzuki, R., Takagi, K. & Satake, T. (1991). Studies on sparfloxacin (SPFX) against respiratory tract infections and its effect on theophylline pharmacokinetics. Chemotherapy (Tokyo) 39, Suppl. 4, 280-5.